Shanghai Rightongene Biotechnology Co., Ltd. (SHA:688217)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Diagnostic Kits/Equipment	177.26M	242.31M	258.21M	424.30M	290.95M
Diagnostic Kits/Equipment Growth	-26.84%	-6.16%	-39.14%	45.83%	2.11%
Total	177.26M	242.31M	258.21M	424.30M	290.95M
Total Growth	-26.84%	-6.16%	-39.14%	45.83%	2.11%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
China	177.26M	242.31M	258.21M	424.30M	290.95M
China Growth	-26.84%	-6.16%	-39.14%	45.83%	2.11%
Total	177.26M	242.31M	258.21M	424.30M	290.95M
Total Growth	-26.84%	-6.16%	-39.14%	45.83%	2.11%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 12, 2026

Data Sources Report a data error